Dusseldorf - Delayed Quote EUR

AstraZeneca PLC (ZEG.DU)

121.90

+1.00

+(0.83%)

At close: April 24 at 7:32:21 PM GMT+2

Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

Earnings preview of key companies reporting next week and what to look out for.

Yahoo Finance UK 2 minutes ago

KHC

PUGBY

PUIGF
AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial

AstraZeneca (LSE:AZN) recently reported a 1.9% decline in its share price over the last week. This movement coincides with the broader market's downturn, which saw a 1.1% drop amid ongoing concerns about international trade, particularly following U.S. tariff policies. Amid these market pressures, the company's collaboration with Daiichi Sankyo was highlighted by the announcement of successful phase 3 trial results for ENHERTU, which positively impacts the oncology sector. Although...

Simply Wall St. 3 days ago

AZN

AZNCF
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer

WILMINGTON, Del., April 21, 2025--Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzumab (THP) as a 1st-line treatment for patients with HER2-positive metastatic breast cancer.

Business Wire 3 days ago

AZN

AZNCF
Six FTSE 100 stock ideas for the second quarter, according to Barclays

While uncertainty remains high amid Trump's tariff blitz, Barclays analysts have highlighted six UK stock ideas for the second quarter.

Yahoo Finance UK 7 days ago

^GSPC

IMBBF

IMBBY
Trending tickers: TSMC, Trump Media, US Steel, Novo Nordisk and Tesco

The latest investor updates on stocks that are trending on Thursday.

Yahoo Finance UK 14 days ago

STZ

^DJI

TSM
AstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAY

AstraZeneca (LSE:AZN) saw its share price decline by 3.5% in the last quarter, a period marked by several key developments, including the European approval of DATROWAY for breast cancer treatment and Imfinzi in non-small cell lung cancer. Despite these approvals, which could positively impact long-term prospects, broader market volatility weighed on the company's performance. Notably, President Trump's tariff threats against pharmaceutical companies likely added further pressure, as the...

Simply Wall St. 15 days ago

AZN

AZNCF
Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’

(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.President Donald Trump said his long-promised tariffs on pharmaceutical drugs will be coming soon, the latest signal that he plans to press ahead with more sectoral tariffs despite market fallout from his global levies.“We are going to be announcing very shortly a major tariff on pharmaceuticals,” Trump said Tuesday at a fundraising gala for House Republicans, without providing details on the planned levy.“O

Bloomberg 15 days ago

BMY

CELG-RT

PFE
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca

The latest investor updates on stocks that are trending on Wednesday.

Yahoo Finance UK 15 days ago

DAL

GM

SVNDF
AstraZeneca (LSE:AZN) Secures EU Approvals; $125 Million Payment Due to Daiichi Sankyo

AstraZeneca (LSE:AZN) has seen a shift recently with the EU approval of ENHERTU® and Imfinzi®, which are likely influential in its 8% share price increase over the last quarter. These regulatory milestones highlight the company's advancements in oncology treatments. Meanwhile, the market has been volatile, with major indices experiencing significant declines amid global trade tensions and economic uncertainty, with the Dow Jones down 4%. Despite this backdrop, AstraZeneca has outperformed,...

Simply Wall St. 20 days ago

AZN

AZNCF
AstraZeneca PLC's (LON:AZN) Stock Has Fared Decently: Is the Market Following Strong Financials?

AstraZeneca's (LON:AZN) stock up by 7.5% over the past three months. Since the market usually pay for a company’s...

Simply Wall St. 20 days ago

AZN

AZNCF
Spirits, Swiss Watches, Sneakers: Global Stock-Market Winners and Losers from Tariffs

Here are some notable moves across sectors in global markets, following President Trump’s “Liberation Day” tariffs. Some investors turned to drink: Scotch producer Diageo and Aperol maker Campari were among the few risers in Europe. This is mostly about their imports from Mexico and Canada, brokers say, after the White House kept duty-free access to the U.S. for USMCA-compliant products.

The Wall Street Journal 21 days ago

NKE

AZN

AZNCF
How Trump's tariffs will impact your finances and the UK economy

Keir Starmer has admitted the US president's trade war will hurt the UK economy.

Yahoo Finance UK 21 days ago

LVMHF

LVMUY

GBPEUR=X
Trending tickers: Nvidia, Tesla, Nike, AstraZeneca and Standard Chartered

The latest investor updates on stocks that are trending on Thursday.

Yahoo Finance UK 21 days ago

GBPEUR=X

GBP=X

EUR=X
Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins

The latest investor updates on stocks that are trending on Tuesday.

Yahoo Finance UK 23 days ago

^DJI

GBPEUR=X

GBP=X
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. But AstraZeneca stock fell in line with pharma stocks.

Investor's Business Daily 24 days ago

NAMS

NAMSW

AZN
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

WILMINGTON, Del., March 31, 2025--Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo.1,2 AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care-lipid lowering therapies such as statins.1,2

Business Wire 24 days ago

AZN

AZNCF
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

WILMINGTON, Del., March 31, 2025--AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).

Business Wire 24 days ago

AZN

AZNCF
AstraZeneca says new results reinforce Tagrisso as backbone therapy

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include: LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy; SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with h

TipRanks 29 days ago

AZN

AZNCF
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

WILMINGTON, Del., March 25, 2025--New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Highlights include:

Business Wire 30 days ago

AZN

AZNCF
Micron, Johnson & Johnson, AstraZeneca: Top Stocks

Morning Brief host Brad Smith tracks several of this morning's trending stocks and market stories, including Micron Technology's (MU) guidance overshadowing its fiscal second quarter results, Johnson & Johnson's (JNJ) plans to invest in US manufacturing, and AstraZeneca's (AZN) own investment into a Beijing facility. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video last month

MU

AZN

AZNCF

Performance Overview

Return	ZEG.DU	FTSE 100 (^FTSE)
YTD	-2.78%	+2.87%
1-Year	-6.25%	+4.56%
3-Year	+5.25%	+11.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (ZEG.DU)

Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer

Six FTSE 100 stock ideas for the second quarter, according to Barclays

Trending tickers: TSMC, Trump Media, US Steel, Novo Nordisk and Tesco

AstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAY

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’

Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca

AstraZeneca (LSE:AZN) Secures EU Approvals; $125 Million Payment Due to Daiichi Sankyo

AstraZeneca PLC's (LON:AZN) Stock Has Fared Decently: Is the Market Following Strong Financials?

Spirits, Swiss Watches, Sneakers: Global Stock-Market Winners and Losers from Tariffs

How Trump's tariffs will impact your finances and the UK economy

Trending tickers: Nvidia, Tesla, Nike, AstraZeneca and Standard Chartered

Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

AstraZeneca says new results reinforce Tagrisso as backbone therapy

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Micron, Johnson & Johnson, AstraZeneca: Top Stocks

Performance Overview

News

Life

Entertainment

Finance

Sports

New on Yahoo

AstraZeneca PLC (ZEG.DU)

Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer

Six FTSE 100 stock ideas for the second quarter, according to Barclays

Trending tickers: TSMC, Trump Media, US Steel, Novo Nordisk and Tesco

AstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAY

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’

Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca

AstraZeneca (LSE:AZN) Secures EU Approvals; $125 Million Payment Due to Daiichi Sankyo

AstraZeneca PLC's (LON:AZN) Stock Has Fared Decently: Is the Market Following Strong Financials?

Spirits, Swiss Watches, Sneakers: Global Stock-Market Winners and Losers from Tariffs

How Trump's tariffs will impact your finances and the UK economy

Trending tickers: Nvidia, Tesla, Nike, AstraZeneca and Standard Chartered

Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

AstraZeneca says new results reinforce Tagrisso as backbone therapy

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Micron, Johnson & Johnson, AstraZeneca: Top Stocks

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial